Jun

26

ZURICH, June 25 (Reuters) - Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday

Biosimilars are viewed as a promising new market, given the pent-up demand for cheaper versions of extremely expensive biotech drugs, some of which are coming to the end of their patent life.

Somatropin, made by Novartis’ generics unit Sandoz, is for treatment of growth hormone deficiency in children and growth disturbance associated with Turner’s syndrome or chronic renal insufficiency, the group said.

Even though it is touted as a “fountain of youth” drug, HGH has the potential for side effects. Read about the benefits of an all natural HGH product that has NO side effects, and is 100% legal. Click here!

Read the entire HGH article.


Comments

Name (required)

Email (required)

Website

Speak your mind

Comments are closed.